Genmab to receive $16 million on Arzerra approval

Tuesday 20 April 2010

Genmab A/S is set to receive DKK 87 million ($16 million) from GlaxoSmithKline Plc following the conditional approval in Europe of Arzerra (ofatumumab), its treatment for refractory chronic lymphocytic leukaemia (CLL).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark